Chinook Therapeutics Announces Partnership with Ionis to Develop Antisense Therapy for Rare, Severe Chronic Kidney Disease
May 16 2023 - 7:00AM
Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has
entered a collaboration agreement with Ionis Pharmaceuticals, Inc.
for the discovery, development and commercialization of an
antisense oligonucleotide (ASO) therapy for a rare, severe chronic
kidney disease with significant unmet medical need. The companies
will leverage Chinook’s precision medicine approach and deep
expertise in nephrology and Ionis’ extensive expertise in
RNA-targeted therapeutics.
“We are pleased to collaborate with Ionis on this preclinical
discovery program as we continue to strengthen Chinook’s position
as the leading kidney disease company,” said Andrew King, D.V.M,
Ph.D., chief scientific officer of Chinook. “Developing an ASO
therapy enhances our ability to target key genetic and molecular
drivers and expands our precision medicine pipeline for rare severe
chronic kidney diseases while continuing to pursue our goal of
making dialysis and transplant unnecessary for people living with
kidney disease.”
Under the terms of the agreement, Chinook will pay Ionis an
undisclosed upfront payment as well as potential development and
regulatory milestone payments and royalties. Ionis will be
responsible for IND-enabling toxicology studies and Chinook will be
responsible for clinical development and commercialization.
About Antisense TechnologyAntisense therapies
are designed to seek out, bind to and destroy a mRNA in a highly
specific manner, so that the amount of disease-causing protein is
dramatically decreased. Antisense therapies can also treat diseases
caused by too little protein by increasing the production of the
protein, thereby restoring the protein to normal levels.
About Chinook Therapeutics, Inc.Chinook
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
developing precision medicines for kidney diseases. Chinook’s
product candidates are being investigated in rare, severe chronic
kidney disorders with opportunities for well-defined clinical
pathways. Chinook’s lead program is atrasentan, a phase 3
endothelin receptor antagonist for the treatment of IgA nephropathy
and proteinuric glomerular diseases. BION-1301, an anti-APRIL
monoclonal antibody, is being evaluated in a phase 1/2 trial for
IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for
the treatment of hyperoxalurias, is in phase 1 development. In
addition, Chinook’s research and discovery efforts are focused on
building a pipeline of precision medicines for rare, severe chronic
kidney diseases with defined genetic and molecular drivers. Chinook
is leveraging insights from kidney single cell RNA sequencing and
large CKD patient cohorts that have been comprehensively
panomically phenotyped, with retained biosamples and prospective
clinical follow-up, to discover and develop therapeutic candidates
with mechanisms of action targeted against key kidney disease
pathways. To learn more, visit www.chinooktx.com.
Chinook’s Cautionary Note on Forward-Looking
StatementsCertain of the statements made in this press
release are forward looking, including those relating to Chinook’s
business, future operations, advancement of its product candidates
and product pipeline, clinical development of its product
candidates, including expectations regarding cash forecasts and
timing of initiation and results of clinical trials, and regulatory
submissions, including the timing of the results of our phase 3
ALIGN trial and phase 2 AFFINITY trial of atrasentan, phase 3
clinical trial of BION-1301, phase 1/2 trial of BION-1301, the
resumption of dosing in our phase 1 clinical trial of CHK-336, and
submission for potential accelerated approval for atrasentan. In
some cases, you can identify these statements by forward-looking
words such as “may,” “will,” “continue,” “anticipate,” “intend,”
“could,” “project,” “expect” or the negative or plural of these
words or similar expressions. Forward-looking statements are not
guarantees of future performance and are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including, but not limited to,
our ability to develop and commercialize our product candidates,
including initiation of clinical trials of our existing product
candidates or those developed as part of the Evotec collaboration
or other strategic collaborations, including this collaboration
with Ionis, whether results of early clinical trials or preclinical
studies will be indicative of the results of future trials,
including our phase 3 ALIGN trial, our ability to obtain and
maintain regulatory approval of our product candidates, our ability
to operate in a competitive industry and compete successfully
against competitors that may be more advanced or have greater
resources than we do, our ability to obtain and adequately protect
intellectual property rights for our product candidates, and the
effects of macroeconomic conditions on our business operations,
including rising interest rates and inflation. Many of these risks
are described in greater detail in our filings with the SEC. Any
forward-looking statements in this press release speak only as of
the date of this press release. Chinook assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Investor Contact:
Noopur Liffick, MPH
Senior Vice President, Investor Relations & Corporate Communications
investors@chinooktx.com
Media Contact:
Kelly North
Senior Manager, Investor Relations & Corporate Communications
media@chinooktx.com
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From Apr 2024 to May 2024
Chinook Therapeutics (NASDAQ:KDNY)
Historical Stock Chart
From May 2023 to May 2024